PA8627601A1 - Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos - Google Patents

Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos

Info

Publication number
PA8627601A1
PA8627601A1 PA20058627601A PA8627601A PA8627601A1 PA 8627601 A1 PA8627601 A1 PA 8627601A1 PA 20058627601 A PA20058627601 A PA 20058627601A PA 8627601 A PA8627601 A PA 8627601A PA 8627601 A1 PA8627601 A1 PA 8627601A1
Authority
PA
Panama
Prior art keywords
hydrocloride
ilo
triptase
inhibitor
compound
Prior art date
Application number
PA20058627601A
Other languages
English (en)
Spanish (es)
Inventor
Adam W Sledeski
Zhongli Gao
Larry Davis
Julian Levell
Mark Czekaj
Haddad El-Bdaoui
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of PA8627601A1 publication Critical patent/PA8627601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PA20058627601A 2004-03-26 2005-03-28 Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos PA8627601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26

Publications (1)

Publication Number Publication Date
PA8627601A1 true PA8627601A1 (es) 2006-01-23

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058627601A PA8627601A1 (es) 2004-03-26 2005-03-28 Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos

Country Status (25)

Country Link
US (1) US20070142435A1 (enExample)
EP (1) EP1737848A1 (enExample)
JP (1) JP2007530580A (enExample)
KR (1) KR20060130682A (enExample)
CN (1) CN1956978A (enExample)
AR (1) AR048336A1 (enExample)
AU (1) AU2005230934A1 (enExample)
BR (1) BRPI0509245A (enExample)
CA (1) CA2560649A1 (enExample)
CR (1) CR8603A (enExample)
DO (1) DOP2005000039A (enExample)
EC (1) ECSP066878A (enExample)
IL (1) IL178031A0 (enExample)
MA (1) MA28547B1 (enExample)
MX (1) MXPA06010610A (enExample)
NO (1) NO20064811L (enExample)
PA (1) PA8627601A1 (enExample)
PE (1) PE20060084A1 (enExample)
RU (1) RU2330034C1 (enExample)
TN (1) TNSN06278A1 (enExample)
TW (1) TW200602035A (enExample)
UA (1) UA83738C2 (enExample)
UY (1) UY28821A1 (enExample)
WO (1) WO2005097780A1 (enExample)
ZA (1) ZA200607752B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
AR065859A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Ester de 2,5-dioxo-pirrolidin-1-ilo de acido 4-bromo-3-metil-5-propoxitiofen-2- carboxilico ,su sintesis regioespecifica y un intermedio del mismo
WO2009067202A1 (en) 2007-11-21 2009-05-28 Janssen Pharmaceutica, N.V. Spiropiperidines for use as tryptase inhibitors
CA2713131C (en) * 2008-01-24 2017-01-10 Soligenix, Inc. Topically active steroids for use in interstitial pulmonary fibrosis
CA2734877C (en) * 2008-08-22 2014-04-29 Sanofi-Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011037947A1 (en) 2009-09-24 2011-03-31 Sanofi-Aventis U.S. Llc Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof
JP2013515724A (ja) * 2009-12-23 2013-05-09 サノフイ ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類
MX2012006741A (es) * 2009-12-23 2012-07-04 Sanofi Sa Tratamiento para la enfermedad inflamatoria del intestino.
JP2013515733A (ja) * 2009-12-23 2013-05-09 サノフイ β−トリプターゼインヒビターとしてのインドリル−ピペリジニルベンジルアミン
KR20130009769A (ko) * 2010-02-24 2013-01-23 사노피 피부과 알레르기성 병태의 치료
WO2013054822A1 (en) 2011-10-07 2013-04-18 Takeda Pharmaceutical Company Limited 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
AR110873A1 (es) * 2017-02-10 2019-05-08 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
MXPA02011400A (es) * 2000-05-22 2003-05-23 Aventis Pharm Prod Inc Derivados de arimetilamina para uso como inhibidores de triptasa.

Also Published As

Publication number Publication date
RU2006137717A (ru) 2008-05-10
TW200602035A (en) 2006-01-16
UY28821A1 (es) 2005-10-31
MA28547B1 (fr) 2007-04-03
WO2005097780A1 (en) 2005-10-20
AU2005230934A1 (en) 2005-10-20
TNSN06278A1 (en) 2007-12-03
EP1737848A1 (en) 2007-01-03
NO20064811L (no) 2006-10-23
PE20060084A1 (es) 2006-03-09
AR048336A1 (es) 2006-04-19
US20070142435A1 (en) 2007-06-21
DOP2005000039A (es) 2005-10-31
RU2330034C1 (ru) 2008-07-27
BRPI0509245A (pt) 2007-09-11
ECSP066878A (es) 2006-11-24
JP2007530580A (ja) 2007-11-01
CA2560649A1 (en) 2005-10-20
CN1956978A (zh) 2007-05-02
UA83738C2 (en) 2008-08-11
IL178031A0 (en) 2006-12-31
KR20060130682A (ko) 2006-12-19
CR8603A (es) 2007-06-08
MXPA06010610A (es) 2006-12-15
ZA200607752B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
DOP2010000408A (es) Compuestos quimicos 251
BRPI0914902B8 (pt) Composição farmacêutica para uso no tratamento de mal de parkinson
AR060089A1 (es) Tratamiento del dolor
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
BR112012013252A2 (pt) composição farmacêutica tópica, preservativo, composto, e, uso do mesmo
UY28945A1 (es) Derivados de pirrolopiridina
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BRPI0607536A2 (pt) tratamento de dor
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
BRPI0409380A (pt) composições farmacêuticas